Abstract
The challenges in preventing and controlling tuberculosis are further complicated by the deadly rise of multidrug- resistant tuberculosis (MDR-TB). Recognizing the seriousness of the situation, we initiated a program to screen new agents that would satisfy these unmet needs and have a favorable safety profile. Mycobacteria are well known for their lipid-rich properties. In Mycobacterium tuberculosis, mycolic acid in particular has been established the wall component related to the pathogenesis in the host. There are approximately 250 identified genes related to biosynthesis of the lipid turnover that contain InhA, the main target of isoniazid. Thus, the logical approach for developing a chemotherapy agent against tubercle bacilli included screening compounds that could inhibit the biosyntheses of mycolic acid and that had a novel chemical structure to ensure improved efficacy against MDR-TB. Some of the screening systems established for those purposes and some of the candidates are outlined.
Keywords: Tuberculosis, mycolic acid inhibitor, nitrodehydroimidazooxazole, mycolic acid, BRM test
Current Topics in Medicinal Chemistry
Title: Screening for Novel Antituberculosis Agents that are Effective Against Multidrug Resistant Tuberculosis
Volume: 7 Issue: 5
Author(s): Makoto Matsumoto, Hiroyuki Hashizume, Hidetsugu Tsubouchi, Hirofumi Sasaki, Motohiro Itotani, Hideaki Kuroda, Tatsuo Tomishige, Masanori Kawasaki and Makoto Komatsu
Affiliation:
Keywords: Tuberculosis, mycolic acid inhibitor, nitrodehydroimidazooxazole, mycolic acid, BRM test
Abstract: The challenges in preventing and controlling tuberculosis are further complicated by the deadly rise of multidrug- resistant tuberculosis (MDR-TB). Recognizing the seriousness of the situation, we initiated a program to screen new agents that would satisfy these unmet needs and have a favorable safety profile. Mycobacteria are well known for their lipid-rich properties. In Mycobacterium tuberculosis, mycolic acid in particular has been established the wall component related to the pathogenesis in the host. There are approximately 250 identified genes related to biosynthesis of the lipid turnover that contain InhA, the main target of isoniazid. Thus, the logical approach for developing a chemotherapy agent against tubercle bacilli included screening compounds that could inhibit the biosyntheses of mycolic acid and that had a novel chemical structure to ensure improved efficacy against MDR-TB. Some of the screening systems established for those purposes and some of the candidates are outlined.
Export Options
About this article
Cite this article as:
Matsumoto Makoto, Hashizume Hiroyuki, Tsubouchi Hidetsugu, Sasaki Hirofumi, Itotani Motohiro, Kuroda Hideaki, Tomishige Tatsuo, Kawasaki Masanori and Komatsu Makoto, Screening for Novel Antituberculosis Agents that are Effective Against Multidrug Resistant Tuberculosis, Current Topics in Medicinal Chemistry 2007; 7 (5) . https://dx.doi.org/10.2174/156802607780059727
DOI https://dx.doi.org/10.2174/156802607780059727 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Use of Antioxidants in Sepsis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Single-Dose Microparticle Delivery of a Malaria Transmission- Blocking Vaccine Elicits a Long-Lasting Functional Antibody Response
Current Molecular Medicine Editorial (Hot Topic : Computational Prediction of Drug-Target Interactions in Medicinal Chemistry)
Current Topics in Medicinal Chemistry MIF and the Genetic Basis of Macrophage Responsiveness
Current Immunology Reviews (Discontinued) Impairment of T Cell Immunity by the Respiratory Syncytial Virus: Targeting Virulence Mechanisms for Therapy and Prophylaxis
Current Medicinal Chemistry Dendritic Cell Homeostasis in the Regulation of Self-Reactivity
Current Pharmaceutical Design Heme Oxygenase-1 Dysregulation in the Brain: Implications for HIVAssociated Neurocognitive Disorders
Current HIV Research Monocyte and Macrophage Dysfunction as a Cause of HIV-1 Induced Dysfunction of Innate Immunity
Current Molecular Medicine Pharmacogenomics and Personalized Medicine for the Developing World - Too Soon or Just-in-Time? A Personal View from the World Health Organization
Current Pharmacogenomics and Personalized Medicine Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets The Role of Intrinsically Disordered Regions in the Structure and Functioning of Small Heat Shock Proteins
Current Protein & Peptide Science Simulating the Interactions of Toxins with K+ Channels
Current Pharmaceutical Design Exploring Pharmacological Significance of Chalcone Scaffold: A Review
Current Medicinal Chemistry Mycobacterium tuberculosis DNA Gyrase as a Target for Drug Discovery
Infectious Disorders - Drug Targets Using Xpert MTB/RIF
Current Respiratory Medicine Reviews Applications of Neural Networks in the Medicinal Chemistry Field
Current Medicinal Chemistry - Central Nervous System Agents Synthesis of Isoxazole Moiety Containing Thieno[2,3-d]pyrimidine Derivatives and Preliminarily in vitro Anticancer Activity (Part II)
Anti-Cancer Agents in Medicinal Chemistry 1, 4-Dihydropyridines: A Class of Pharmacologically Important Molecules
Mini-Reviews in Medicinal Chemistry